Quantum Biopharma Ltd. (QNTM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
QNTM currently has 42 outstanding shares. with minimal authorized share overhang for future dilution. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 26, 2026 |
20-F filing | 0.0M shares outstanding |
42 | 0 |
| Mar 28, 2025 |
20-F filing | 0.0M shares outstanding |
72 | 0 |
| Apr 02, 2024 |
20-F filing | 0.0M shares outstanding |
72 | 0 |
| Dec 26, 2023 |
F-3 filing: This is an F-3 filing for a shelf offering of Class B Shares, Subscription Receipts, Warrants and Units. |
72 | 0 |
| Jul 19, 2023 |
RW filing: FSD Pharma Inc. is requesting the U.S. Securities and Exchange Commission to consent to the withdrawal of its Registration Statement on Form F-10 (SEC File No. 333-254995) because the proposed offering of securities contemplated by the Registration Statement has not occurred and will not be proceeding. |
72 | 0 |
| Mar 31, 2023 |
20-F filing | 0.0M shares outstanding |
72 | 0 |
| Mar 31, 2022 |
20-F filing | 0.0M shares outstanding |
72 | 0 |
| Apr 02, 2021 |
F-10 filing: This F-10 filing describes a shelf offering where the Securities qualified hereunder may be offered and sold in one or more offerings, separately or together, in separate series, in such amounts, at such prices and on such terms to be contained in one or more supplements to this Prospectus. |
19M | 0 |
| Mar 17, 2021 |
40-F filing | 19.2M shares outstanding |
19M | 0 |
| Mar 04, 2020 |
40-F filing | 7.1M shares outstanding |
7.1M | 0 |
| Feb 28, 2020 |
F-10 filing: This is an F-10 filing for a shelf offering of securities, including common stock and preferred stock, which may be offered and sold in one or more offerings, separately or together, in separate series, in such amounts, at such prices and on such terms to be contained in one or more supplements to this Prospectus. |
N/A | 0 |